[1] |
Chang MH,Kish TD,Fung HB.Telavancin:a lipoglycopeptide antimicrobial for the treatment of complicated skin and skin structure infections caused by Gram-positive bacteria in adults[J].Clin Ther,2010,32(13):2160-2185.
|
[2] |
Karlowsky JA,Nichol K,Zhanel GG.Telavancin:mechanisms of action,in vitro activity,and mechanisms of resistance[J].Clin Infect Dis,2015,61(Suppl 2):S58-S68.
|
[3] |
Hegde SS, Janc JW. Efficacy of telavancin, a lipoglycopeptide antibiotic,in experimental models of Gram-positive infection[J].Expert Rev Anti-Infe,2014,12(12):1463-1475.
|
[4] |
Higgins DL,Chang R,Debabov DV,et al.Telavancin,a multifunctional lipoglycopeptide,disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus[J].Antimicrob Agents Chemother,2005,49(3):1127-1134.
|
[5] |
Lee J, Liu J. Process for preparing glycopeptide phosphonate derivatives:US,7074890[P].2004-08-25[2016-04-04] .
|
[6] |
Leadbetter MR.Glycopeptide phosphonate derivatives:US,8541375[P].2011-12-16[2016-04-04] .
|
[7] |
Liang YH, Feng WH. Process improvement on the synthesis of lipoglycopeptide antibiotic telavancin[J].Chin J Synt Chem(合成化学),2011,19(4):550-553.
|
[8] |
Ma S,Jia CY,Yuan H,et al.Synthesis of telavancin[J].Chin J New Drugs(中国新药杂志),2013,23(23):2809-2812.
|
[9] |
Benito-Garagorri D. Process for the synthesis of telavancin, its pharmaceutically acceptable salts as well as an N-protected imine-derivative of telavancin:WO,2013034676[P].2011-09-09[2016-04-04] .
|
[10] |
Li XP,Wu JP,Liang XM,et al.Application of DMSO as oxidant in organic syntheses[J].Chin J Org Chem(有机化学),2001,21(8):549-556.
|
[11] |
Tidwell TT.Oxidation of alcohols by activated dimethyl sulfoxide and related reactions:an update[J].Synthesis,1990(10):857-870.DOI: 10.1002/chin.199112358.
|
[12] |
Parikh JR,Doering WE.Sulfur trioxide in the oxidation of alcohols by dimethyl sulfoxide[J].J Am Chem Soc,1967,89(21):5505-5507.
|